2.50
Hdl Handle:
http://hdl.handle.net/2336/35774
Title:
Evidence against PALB2 involvement in Icelandic breast cancer susceptibility
Authors:
Gunnarsson, Haukur; Arason, Adalgeir; Gillanders, Elizabeth M; Agnarsson, Bjarni A; Johannesdottir, Gudrun; Johannsson, Oskar Th; Barkardottir, Rosa B
Citation:
J Negat Results Biomed. 2008, 7:5
Issue Date:
17-Jul-2008
Abstract:
ABSTRACT: Several mutations in the PALB2 gene (partner and localizer of BRCA2) have been associated with an increased risk of breast cancer, including a founder mutation, 1592delT, reported in Finnish breast cancer families. Although most often the risk is moderate, it doesn't exclude families with high-risk mutations to exist and such observations have been reported. To see if high-risk PALB2-mutations may be present in the geographically confined population of Iceland, linkage analysis was done on 111 individuals, thereof 61 breast cancer cases, from 9 high-risk non-BRCA1/BRCA2 breast cancer families, targeting the PALB2 region. Also, screening for the 1592delT founder mutation in the 9 high-risk families and in 638 unselected breast cancer cases was performed. The results indicate no linkage in any of the high-risk families and screening for the 1592delT mutation was negative in all samples. PALB2 appears not to be a significant factor in high-risk breast cancer families in Iceland and the 1592delT mutation is not seen to be associated with breast cancer in Iceland.
Description:
To access full text version of this article. Please click on the hyperlink "View/Open" at the bottom of this page
Additional Links:
http://www.jnrbm.com/content/7/1/5

Full metadata record

DC FieldValue Language
dc.contributor.authorGunnarsson, Haukur-
dc.contributor.authorArason, Adalgeir-
dc.contributor.authorGillanders, Elizabeth M-
dc.contributor.authorAgnarsson, Bjarni A-
dc.contributor.authorJohannesdottir, Gudrun-
dc.contributor.authorJohannsson, Oskar Th-
dc.contributor.authorBarkardottir, Rosa B-
dc.date.accessioned2008-08-18T13:06:03Z-
dc.date.available2008-08-18T13:06:03Z-
dc.date.issued2008-07-17-
dc.date.submitted2008-08-18-
dc.identifier.citationJ Negat Results Biomed. 2008, 7:5en
dc.identifier.issn1477-5751-
dc.identifier.pmid18637200-
dc.identifier.doi10.1186/1477-5751-7-5-
dc.identifier.urihttp://hdl.handle.net/2336/35774-
dc.descriptionTo access full text version of this article. Please click on the hyperlink "View/Open" at the bottom of this pageen
dc.description.abstractABSTRACT: Several mutations in the PALB2 gene (partner and localizer of BRCA2) have been associated with an increased risk of breast cancer, including a founder mutation, 1592delT, reported in Finnish breast cancer families. Although most often the risk is moderate, it doesn't exclude families with high-risk mutations to exist and such observations have been reported. To see if high-risk PALB2-mutations may be present in the geographically confined population of Iceland, linkage analysis was done on 111 individuals, thereof 61 breast cancer cases, from 9 high-risk non-BRCA1/BRCA2 breast cancer families, targeting the PALB2 region. Also, screening for the 1592delT founder mutation in the 9 high-risk families and in 638 unselected breast cancer cases was performed. The results indicate no linkage in any of the high-risk families and screening for the 1592delT mutation was negative in all samples. PALB2 appears not to be a significant factor in high-risk breast cancer families in Iceland and the 1592delT mutation is not seen to be associated with breast cancer in Iceland.en
dc.language.isoenen
dc.publisherBioMed Centralen
dc.relation.urlhttp://www.jnrbm.com/content/7/1/5en
dc.subject.meshGenetic Predisposition to Diseaseen
dc.subject.meshBreast Neoplasmsen
dc.subject.meshTumor Suppressor Proteinsen
dc.titleEvidence against PALB2 involvement in Icelandic breast cancer susceptibilityen
dc.typeArticleen
dc.contributor.departmentDepartment of Pathology, Landspitali - University Hospital, Reykjavik, Iceland. haukur@landspitali.isen
dc.identifier.journalJournal of negative results in biomedicineen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.